RS Research Announces Poster Presentation at the ESMO 2022 Congress about RS-0139’s ongoing clinical trial on NSCLC
22 September 2022
RS Research, a clinical-stage biotechnology start-up developing smart nanomedicines for targeted chemotherapy, announced the acceptance of a poster presentation at the European Society for Medical Oncology (ESMO) 2022 Congress to be held in person on 9-13 September 2022 in Paris – France.
Poster Title: Phase Ia/Ib study of RS-0139, a novel tumor-targeted delivery of docetaxel, in patients with recurrent, locally advanced, or metastatic non-small cell lung cancer (NSCLC)
Date: 12.09.2022
Location: Poster Area, Hall 4
Poster No: 1200TiP
Presenter: Prof. Dr. Hakan S. Orer, Medical Pharmacology, Koc University Hospital; Dr. Gülşah Nomak, Medical Director, RS Research
The poster abstract is available online at the ESMO website.
RS Research (as of Q2 2024)
RS Research was founded by Prof. Rana Sanyal and Sena Nomak to take the necessary steps for bringing innovative therapies to patients, carrying out the research to clinic based on the proprietary drug delivery platforms Sagitta® Bir and Sagitta® Dui. Thanks to this technology, RS Research can increase effectiveness of chemotherapy and reduce side effects, provide patients with an optimal therapeutic index. RS Research raised 2 million Euros seed funding in 2017, followed by a 12 million USD Series-A investment round in 2021. The company developed 5 drug candidates designed based on Sagitta® platform technology addressing multiple indications in its pipeline. RS-0139’s ongoing Phase I clinical trial has advanced to the end of dose finding. Further details regarding the clinical trial are available at clinicaltrials.gov with the trial identifier NCT04261413. RS Research is manufacturing its clinical research products at its own GMP-licensed production facility with both synthesis and filling capability drugs.
For detailed information:
For media inquiries: pr@rsresearch.net
For scientific inquiries: medicalinformation@rsresearch.net
www.rsresearch.net
